SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -40.9% | -90.6% | -60.7% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -262.4% | -67.3% | 86.2% | 97.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,192.5% | -1,703.1% | -63.3% | -25% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,579% | -1,884.5% | -78.4% | -28.2% |
| EPS Diluted | -3.68 | -7.64 | -4.31 | -6.3 |
| % Growth | 51.8% | -77.3% | 31.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |